FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:1493-1499 November 19, 1998 Number 21 Next

	Full Text PDF Editorial by Liang, T. J. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Interferon alfa is the only effective treatment for patients with chronic hepatitis C. Forty percent of patients have an initial response to this therapy, but most subsequently relapse. We compared the effect of interferon alone with that of interferon plus oral ribavirin for relapses of chronic hepatitis C.

Methods We studied 345 patients with chronic hepatitis C who relapsed after interferon treatment. A total of 173 patients were randomly assigned to receive standard-dose recombinant interferon alfa-2b concurrently with ribavirin (1000 to 1200 mg orally per day, depending on body weight) for six months, and 172 patients were assigned to receive interferon and placebo.

Results At the completion of treatment, serum levels of hepatitis C virus (HCV) RNA were undetectable in 141 of the 173 patients who were treated with interferon and ribavirin and in 80 of the 172 patients who were treated with interferon alone (82 percent vs. 47 percent, P<0.001). Serum HCV RNA levels remained undetectable 24 weeks after the end of treatment in 84 patients (49 percent) in the combination-therapy group, but in only 8 patients (5 percent) in the interferon group (P<0.001). Sustained normalization of serum alanine aminotransferase concentrations and histologic improvement were highly correlated with virologic response. Base-line serum HCV RNA levels of 2x10⁶ copies per milliliter or less were associated with higher rates of response in both treatment groups. Viral genotypes other than type 1 were associated with sustained responses only in the combination-therapy group. Combined therapy caused a predictable fall in hemoglobin concentrations but otherwise had a safety profile similar to that of interferon alone.

Conclusions In patients with chronic hepatitis C who relapse after treatment with interferon, therapy with interferon and oral ribavirin results in higher rates of sustained virologic, biochemical, and histologic response than treatment with interferon alone.

Source Information

From the University of Florida College of Medicine, Gainesville (G.L.D.); Hospital Vall d'Hebron, Barcelona, Spain (R.E.-M.); Inova Institute of Research and Education, Falls Church, Va. (V.R.); University of California at Irvine, Orange (J.H.); William Beaumont Hospital, Royal Oak, Mich. (S.C.G.); Hôpital Hotel Dieu, Lyons, France (C.T.); Medical College of Virginia, Richmond (M.L.S.); Klinikum der J.W. Goethe Universität, Frankfurt, Germany (S.Z.); Policlinico P. Giaccone, Palermo, Italy (A.C.); and Schering-Plough Research Institute, Kenilworth, N.J. (M.-H.L., J.A.).

Address reprint requests to Dr. Davis at the Section of Hepatobiliary Diseases, Box 100214, University of Florida College of Medicine, Gainesville, FL 32610-0214.

Full Text of this Article

This article has been cited by other articles:

• Franchini, M., Mengoli, C., Veneri, D., Mazzi, R., Lippi, G., Cruciani, M. (2008). Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis. J Antimicrob Chemother 61: 1191-1200 [Abstract] [Full Text]  
• Murray, K. F., Rodrigue, J. R., Gonzalez-Peralta, R. P., Shepherd, J., Barton, B. A., Robuck, P. R., Schwarz, K. B., for the PEDS-C Clinical Research Network, (2007). Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection. Clin Trials 4: 661-673 [Abstract]  
• Ticehurst, J. R., Hamzeh, F. M., Thomas, D. L. (2007). Factors Affecting Serum Concentrations of Hepatitis C Virus (HCV) RNA in HCV Genotype 1-Infected Patients with Chronic Hepatitis. J. Clin. Microbiol. 45: 2426-2433 [Abstract] [Full Text]  
• Sansonno, D., Carbone, A., De Re, V., Dammacco, F. (2007). Hepatitis C virus infection, cryoglobulinaemia, and beyond. Rheumatology (Oxford) 46: 572-578 [Abstract] [Full Text]  
• Butt, A. A, Justice, A. C, Skanderson, M., Rigsby, M. O, Good, C. B, Kwoh, C K. (2007). Rate and predictors of treatment prescription for hepatitis C. Gut 56: 385-389 [Abstract] [Full Text]  
• Nagaoka, T., Sato, E., Takahashi, A., Yokohama, S., Yoshida, A. (2007). Retinal Circulatory Changes Associated with Interferon-Induced Retinopathy in Patients with Hepatitis C. IOVS 48: 368-375 [Abstract] [Full Text]  
• LIVONESI, M. C., DE SOUSA, R. L. M., BADRA, S. J., FIGUEIREDO, L. T.M. (2006). IN VITRO AND IN VIVO STUDIES OF RIBAVIRIN ACTION ON BRAZILIAN ORTHOBUNYAVIRUS. Am J Trop Med Hyg 75: 1011-1016 [Abstract] [Full Text]  
• Sherman, M, Yoshida, E M, Deschenes, M, Krajden, M, Bain, V G, Peltekian, K, Anderson, F, Kaita, K, Simonyi, S, Balshaw, R, Lee, S S, the Canadian Pegasys Study Group, (2006). Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 55: 1631-1638 [Abstract] [Full Text]  
• Saito, H., Tada, S., Ebinuma, H., Ishii, H., Kashiwazaki, K., Takahashi, M., Tsukada, N., Nishida, J., Tanaka, S., Shiozaki, H., Hibi, T. (2006). Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections.. J. Clin. Microbiol. 44: 3562-3568 [Abstract] [Full Text]  
• Khader, Y. S., Dweek, A., Alkafajei, A., Rabi', A. Z. (2006). Combination Therapy of Interferon and Ribavirin Versus Interferon Monotherapy in Treatment of Chronic Hepatitis C: A Meta-analysis of Clinical Trials. Journal of Pharmacy Practice 19: 265-274 [Abstract]  
• Crone, C. C., Gabriel, G. M., DiMartini, A. (2006). An Overview of Psychiatric Issues in Liver Disease for the Consultation-Liaison Psychiatrist. Psychosomatics 47: 188-205 [Abstract] [Full Text]  
• Mistler, L. A., Brunette, M. F., Marsh, B. J., Vidaver, R. M., Luckoor, R., Rosenberg, S. D. (2006). Hepatitis C treatment for people with severe mental illness.. Psychosomatics 47: 93-107 [Abstract] [Full Text]  
• Wang, C.-Q., Li, Y., Douglas, S. D., Wang, X., Metzger, D. S., Zhang, T., Ho, W.-Z. (2005). Morphine Withdrawal Enhances Hepatitis C Virus Replicon Expression. Am. J. Pathol. 167: 1333-1340 [Abstract] [Full Text]  
• Brok, J., Gluud, L. L., Gluud, C. (2005). Effects of Adding Ribavirin to Interferon to Treat Chronic Hepatitis C Infection: A Systematic Review and Meta-analysis of Randomized Trials. Arch Intern Med 165: 2206-2212 [Abstract] [Full Text]  
• Vecchiet, J., Falasca, K., Cacciatore, P., Zingariello, P., Dalessandro, M., Marinopiccoli, M., D'Amico, E., Palazzi, C., Petrarca, C., Conti, P., Pizzigallo, E., Guagnano, M. T. (2005). Association between Plasma Interleukin-18 Levels and Liver Injury in Chronic Hepatitis C Virus Infection and Non-Alcoholic Fatty Liver Disease. Annals of Clinical & Laboratory Science 35: 415-422 [Abstract] [Full Text]  
• Hwang, D.-R., Lin, R.-K., Leu, G.-Z., Lin, T.-Y., Lien, T.-W., Yu, M.-C., Yeh, C.-T., Hsu, J. T.-A. (2005). Inhibition of Hepatitis C Virus Replication by Antimonial Compounds. Antimicrob. Agents Chemother. 49: 4197-4202 [Abstract] [Full Text]  
• Mo, H., Lu, L., Pilot-Matias, T., Pithawalla, R., Mondal, R., Masse, S., Dekhtyar, T., Ng, T., Koev, G., Stoll, V., Stewart, K. D., Pratt, J., Donner, P., Rockway, T., Maring, C., Molla, A. (2005). Mutations Conferring Resistance to a Hepatitis C Virus (HCV) RNA-Dependent RNA Polymerase Inhibitor Alone or in Combination with an HCV Serine Protease Inhibitor In Vitro. Antimicrob. Agents Chemother. 49: 4305-4314 [Abstract] [Full Text]  
• Naas, T., Ghorbani, M., Alvarez-Maya, I., Lapner, M., Kothary, R., De Repentigny, Y., Gomes, S., Babiuk, L., Giulivi, A., Soare, C., Azizi, A., Diaz-Mitoma, F. (2005). Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2. J. Gen. Virol. 86: 2185-2196 [Abstract] [Full Text]  
• Murray, T. S., Groth, M. E., Weitzman, C., Cappello, M. (2005). Epidemiology and Management of Infectious Diseases in International Adoptees. Clin. Microbiol. Rev. 18: 510-520 [Abstract] [Full Text]  
• Schmid, M, Kreil, A, Jessner, W, Homoncik, M, Datz, C, Gangl, A, Ferenci, P, Peck-Radosavljevic, M (2005). Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon {alpha} mono and combination therapy regimens. Gut 54: 1014-1020 [Abstract] [Full Text]  
• Aurisicchio, L., De Tomassi, A., La Monica, N., Ciliberto, G., Traboni, C., Palombo, F. (2005). Regulated and Liver-Specific Tamarin Alpha Interferon Gene Delivery by a Helper-Dependent Adenoviral Vector. J. Virol. 79: 6772-6780 [Abstract] [Full Text]  
• Puig-Basagoiti, F., Forns, X., Furcic, I., Ampurdanes, S., Gimenez-Barcons, M., Franco, S., Sanchez-Tapias, J. M., Saiz, J.-C. (2005). Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. J. Gen. Virol. 86: 1067-1075 [Abstract] [Full Text]  
• Takahashi, M., Saito, H., Higashimoto, M., Atsukawa, K., Ishii, H. (2005). Benefit of Hepatitis C Virus Core Antigen Assay in Prediction of Therapeutic Response to Interferon and Ribavirin Combination Therapy. J. Clin. Microbiol. 43: 186-191 [Abstract] [Full Text]  
• Li, Y., Zhang, T., Ho, C., Orange, J. S., Douglas, S. D., Ho, W.-Z. (2004). Natural killer cells inhibit hepatitis C virus expression. J. Leukoc. Biol. 76: 1171-1179 [Abstract] [Full Text]  
• Ranjith-Kumar, C. T., Sarisky, R. T., Gutshall, L., Thomson, M., Kao, C. C. (2004). De Novo Initiation Pocket Mutations Have Multiple Effects on Hepatitis C Virus RNA-Dependent RNA Polymerase Activities. J. Virol. 78: 12207-12217 [Abstract] [Full Text]  
• Malek-Ahmadi, P., Ghandour, E. (2004). Bupropion for Treatment of Interferon-Induced Depression. The Annals of Pharmacotherapy 38: 1202-1205 [Abstract] [Full Text]  
• Fargion, S., Fracanzani, A. L., Valenti, L. (2004). Treatment choices for people infected with HCV. J Antimicrob Chemother 53: 708-712 [Abstract] [Full Text]  
• Lin, C., Lin, K., Luong, Y.-P., Rao, B. G., Wei, Y.-Y., Brennan, D. L., Fulghum, J. R., Hsiao, H.-M., Ma, S., Maxwell, J. P., Cottrell, K. M., Perni, R. B., Gates, C. A., Kwong, A. D. (2004). In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061: STRUCTURAL ANALYSIS INDICATES DIFFERENT RESISTANCE MECHANISMS. J. Biol. Chem. 279: 17508-17514 [Abstract] [Full Text]  
• Zeuzem, S. (2004). Heterogeneous Virologic Response Rates to Interferon-Based Therapy in Patients with Chronic Hepatitis C: Who Responds Less Well?. ANN INTERN MED 140: 370-381 [Abstract] [Full Text]  
• Henry, D. H., Bowers, P., Romano, M. T., Provenzano, R. (2004). Epoetin Alfa: Clinical Evolution of a Pleiotropic Cytokine. Arch Intern Med 164: 262-276 [Abstract] [Full Text]  
• Gochee, P. A., Powell, E. E., Purdie, D. M., Pandeya, N., Kelemen, L., Shorthouse, C., Jonsson, J. R., Kelly, B. (2004). Association Between Apolipoprotein E {epsilon}4 and Neuropsychiatric Symptoms During Interferon {alpha} Treatment for Chronic Hepatitis C. Psychosomatics 45: 49-57 [Abstract] [Full Text]  
• Elbeik, T., Surtihadi, J., Destree, M., Gorlin, J., Holodniy, M., Jortani, S. A., Kuramoto, K., Ng, V., Valdes, R. Jr., Valsamakis, A., Terrault, N. A. (2004). Multicenter Evaluation of the Performance Characteristics of the Bayer VERSANT HCV RNA 3.0 Assay (bDNA). J. Clin. Microbiol. 42: 563-569 [Abstract] [Full Text]  
• Moore, M. M., Elpern, D. J., Carter, D. J. (2004). Severe, Generalized Nummular Eczema Secondary to Interferon Alfa-2b Plus Ribavirin Combination Therapy in a Patient With Chronic Hepatitis C Virus Infection. Arch Dermatol 140: 215-217 [Abstract] [Full Text]  
• Morishima, C., Chung, M., Ng, K. W., Brambilla, D. J., Gretch, D. R. (2004). Strengths and Limitations of Commercial Tests for Hepatitis C Virus RNA Quantification. J. Clin. Microbiol. 42: 421-425 [Abstract] [Full Text]  
• Bougie, I., Bisaillon, M. (2003). Initial Binding of the Broad Spectrum Antiviral Nucleoside Ribavirin to the Hepatitis C Virus RNA Polymerase. J. Biol. Chem. 278: 52471-52478 [Abstract] [Full Text]  
• Li, Y., Zhang, T., Douglas, S. D., Lai, J.-P., Xiao, W.-D., Pleasure, D. E., Ho, W.-Z. (2003). Morphine Enhances Hepatitis C Virus (HCV) Replicon Expression. Am. J. Pathol. 163: 1167-1175 [Abstract] [Full Text]  
• Zhong, W., An, H., Barawkar, D., Hong, Z. (2003). Dinucleotide Analogues as Novel Inhibitors of RNA-Dependent RNA Polymerase of Hepatitis C Virus. Antimicrob. Agents Chemother. 47: 2674-2681 [Abstract] [Full Text]  
• Tedeschi, R., Pivetta, E., Zanussi, S., Bidoli, E., Ros, M., di Gennaro, G., Nasti, G., De Paoli, P. (2003). Quantification of Hepatitis C Virus (HCV) in Liver Specimens and Sera from Patients with Human Immunodeficiency Virus Coinfection by Using the Versant HCV RNA 3.0 (Branched DNA-Based) DNA Assay. J. Clin. Microbiol. 41: 3046-3050 [Abstract] [Full Text]  
• Schlosser, S. F., Schuler, M., Berg, C. P., Lauber, K., Schulze-Osthoff, K., Schmahl, F. W., Wesselborg, S. (2003). Ribavirin and Alpha Interferon Enhance Death Receptor-Mediated Apoptosis and Caspase Activation in Human Hepatoma Cells. Antimicrob. Agents Chemother. 47: 1912-1921 [Abstract] [Full Text]  
• Gault, E., Soussan, P., Morice, Y., Sanders, L., Berrada, A., Rogers, B., Deny, P. (2003). Evaluation of a New Serotyping Assay for Detection of Anti-Hepatitis C Virus Type-Specific Antibodies in Serum Samples. J. Clin. Microbiol. 41: 2084-2087 [Abstract] [Full Text]  
• Adinolfi, L E, Utili, R, Tonziello, A, Ruggiero, G (2003). Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial. Gut 52: 701-705 [Abstract] [Full Text]  
• Prieto, J, Herraiz, M, Sangro, B, Qian, C, Mazzolini, G, Melero, I, Ruiz, J (2003). The promise of gene therapy in gastrointestinal and liver diseases. Gut 52: ii49-54 [Abstract] [Full Text]  
• Corbet, S., Bukh, J., Heinsen, A., Fomsgaard, A. (2003). Hepatitis C Virus Subtyping by a Core-Envelope 1-Based Reverse Transcriptase PCR Assay with Sequencing and Its Use in Determining Subtype Distribution among Danish Patients. J. Clin. Microbiol. 41: 1091-1100 [Abstract] [Full Text]  
• Reddy, S. I., Ukomadu, C. (2003). Viral Hepatitis and Hepatocellular Carcinoma in African Americans. Cancer Epidemiol. Biomarkers Prev. 12: 248S-251 [Full Text]  
• Lee, S. S., Abdo, A. A. (2003). Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon?. J Antimicrob Chemother 51: 487-491 [Full Text]  
• Kapadia, S. B., Brideau-Andersen, A., Chisari, F. V. (2003). Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc. Natl. Acad. Sci. USA 100: 2014-2018 [Abstract] [Full Text]  
• Shiratori, Y., Shiina, S., Teratani, T., Imamura, M., Obi, S., Sato, S., Koike, Y., Yoshida, H., Omata, M. (2003). Interferon Therapy after Tumor Ablation Improves Prognosis in Patients with Hepatocellular Carcinoma Associated with Hepatitis C Virus. ANN INTERN MED 138: 299-306 [Abstract] [Full Text]  
• Wu, J. Z., Walker, H., Lau, J. Y. N., Hong, Z. (2003). Activation and Deactivation of a Broad-Spectrum Antiviral Drug by a Single Enzyme: Adenosine Deaminase Catalyzes Two Consecutive Deamination Reactions. Antimicrob. Agents Chemother. 47: 426-431 [Abstract] [Full Text]  
• Kim, J. W., Seo, M. Y., Shelat, A., Kim, C. S., Kwon, T. W., Lu, H.-h., Moustakas, D. T., Sun, J., Han, J. H. (2002). Structurally Conserved Amino Acid W501 Is Required for RNA Helicase Activity but Is Not Essential for DNA Helicase Activity of Hepatitis C Virus NS3 Protein. J. Virol. 77: 571-582 [Abstract] [Full Text]  
• Camma, C, Bruno, S, Schepis, F, Lo Iacono, O, Andreone, P, Gramenzi, A G, Mangia, A, Andriulli, A, Puoti, M, Spadaro, A, Freni, M, Di Marco, V, Cino, L, Saracco, G, Chiesa, A, Crosignani, A, Caporaso, N, Morisco, F, Rumi, M G, Craxi, A (2002). Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. Gut 51: 864-869 [Abstract] [Full Text]  
• Bullock, G. C., Bruns, D. E., Haverstick, D. M. (2002). Hepatitis C Genotype Determination by Melting Curve Analysis with a Single Set of Fluorescence Resonance Energy Transfer Probes. Clin. Chem. 48: 2147-2154 [Abstract] [Full Text]  
• Ezelle, H. J., Markovic, D., Barber, G. N. (2002). Generation of Hepatitis C Virus-Like Particles by Use of a Recombinant Vesicular Stomatitis Virus Vector. J. Virol. 76: 12325-12334 [Abstract] [Full Text]  
• Cheney, I. W., Lai, V. C. H., Zhong, W., Brodhag, T., Dempsey, S., Lim, C., Hong, Z., Lau, J. Y. N., Tam, R. C. (2002). Comparative Analysis of Anti-Hepatitis C Virus Activity and Gene Expression Mediated by Alpha, Beta, and Gamma Interferons. J. Virol. 76: 11148-11154 [Abstract] [Full Text]  
• Fontana, R. J., Schwartz, S. M., Gebremariam, A., Lok, A. S.F., Moyer, C. A. (2002). Emotional Distress During Interferon-{alpha}-2B and Ribavirin Treatment of Chronic Hepatitis C. Psychosomatics 43: 378-385 [Abstract] [Full Text]  
• Chen, Z., Weck, K. E. (2002). Hepatitis C Virus Genotyping: Interrogation of the 5' Untranslated Region Cannot Accurately Distinguish Genotypes 1a and 1b. J. Clin. Microbiol. 40: 3127-3134 [Abstract] [Full Text]  
• Jain, J., Almquist, S. J., Heiser, A. D., Shlyakhter, D., Leon, E., Memmott, C., Moody, C. S., Nimmesgern, E., Decker, C. (2002). Characterization of Pharmacological Efficacy of VX-148, a New, Potent Immunosuppressive Inosine 5'-Monophosphate Dehydrogenase Inhibitor. J. Pharmacol. Exp. Ther. 302: 1272-1277 [Abstract] [Full Text]  
• Zhang, X.-M., Mitchell, D. G., Shi, H., Holland, G. A., Parker, L., Herrine, S. K., Pasqualin, D., Rubin, R. (2002). Chronic Hepatitis C Activity: Correlation with Lymphadenopathy on MR Imaging. Am. J. Roentgenol. 179: 417-422 [Abstract] [Full Text]  
• Hickman, I J, Clouston, A D, Macdonald, G A, Purdie, D M, Prins, J B, Ash, S, Jonsson, J R, Powell, E E (2002). Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 51: 89-94 [Abstract] [Full Text]  
• Trimoulet, P., Halfon, P., Pohier, E., Khiri, H., Chene, G., Fleury, H. (2002). Evaluation of the VERSANT HCV RNA 3.0 Assay for Quantification of Hepatitis C Virus RNA in Serum. J. Clin. Microbiol. 40: 2031-2036 [Abstract] [Full Text]  
• Herrine, S. K. (2002). Approach to the Patient with Chronic Hepatitis C Virus Infection. ANN INTERN MED 136: 747-757 [Abstract] [Full Text]  
• Kelly, D, Skidmore, S (2002). Hepatitis C-Z: recent advances. Arch. Dis. Child. 86: 339-343 [Abstract] [Full Text]  
• Wang, T. Y., Kuo, H. T., Chen, L. C., Chen, Y. T., Lin, C. N., Lee, M. M. (2002). Use of Polymerase Chain Reaction for Early Detection and Management of Hepatitis C Virus Infection after Needlestick Injury. Annals of Clinical & Laboratory Science 32: 137-141 [Abstract] [Full Text]  
• Farci, P., Strazzera, R., Alter, H. J., Farci, S., Degioannis, D., Coiana, A., Peddis, G., Usai, F., Serra, G., Chessa, L., Diaz, G., Balestrieri, A., Purcell, R. H. (2002). Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc. Natl. Acad. Sci. USA 99: 3081-3086 [Abstract] [Full Text]  
• Konnick, E. Q., Erali, M., Ashwood, E. R., Hillyard, D. R. (2002). Performance Characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, Version 2.0, International Unit Assay and the National Genetics Institute HCV Superquant Assay. J. Clin. Microbiol. 40: 768-773 [Abstract] [Full Text]  
• Germer, J. J., Heimgartner, P. J., Ilstrup, D. M., Harmsen, W. S., Jenkins, G. D., Patel, R. (2002). Comparative Evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR Version 2.0 Assays for Quantification of Hepatitis C Virus RNA in Serum. J. Clin. Microbiol. 40: 495-500 [Abstract] [Full Text]  
• Santagostino, E., Rumi, M. G., Rivi, M., Colombo, M., Mannucci, P. M. (2002). Sustained suppression of hepatitis C virus by interferon and ribavirin in hemophilic patients not responding to interferon monotherapy. Blood 99: 1089-1091 [Abstract] [Full Text]  
• Kjaergard, L. L, Krogsgaard, K., Gluud, C. (2001). Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ 323: 1151-1155 [Abstract] [Full Text]  
• Pariente, N., Sierra, S., Lowenstein, P. R., Domingo, E. (2001). Efficient Virus Extinction by Combinations of a Mutagen and Antiviral Inhibitors. J. Virol. 75: 9723-9730 [Abstract] [Full Text]  
• Samuel, C. E. (2001). Antiviral Actions of Interferons. Clin. Microbiol. Rev. 14: 778-809 [Abstract] [Full Text]  
• Jain, K, Lam, W C, Waheeb, S, Thai, Q, Heathcote, J (2001). Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br. J. Ophthalmol. 85: 1171-1173 [Abstract] [Full Text]  
• Guo, J.-T., Bichko, V. V., Seeger, C. (2001). Effect of Alpha Interferon on the Hepatitis C Virus Replicon. J. Virol. 75: 8516-8523 [Abstract] [Full Text]  
• Weiner, A. J., Paliard, X., Selby, M. J., Medina-Selby, A., Coit, D., Nguyen, S., Kansopon, J., Arian, C. L., Ng, P., Tucker, J., Lee, C.-T., Polakos, N. K., Han, J., Wong, S., Lu, H.-H., Rosenberg, S., Brasky, K. M., Chien, D., Kuo, G., Houghton, M. (2001). Intrahepatic Genetic Inoculation of Hepatitis C Virus RNA Confers Cross-Protective Immunity. J. Virol. 75: 7142-7148 [Abstract] [Full Text]  
• Chung, R. T., He, W., Saquib, A., Contreras, A. M., Xavier, R. J., Chawla, A., Wang, T. C., Schmidt, E. V. (2001). Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system. Proc. Natl. Acad. Sci. USA 10.1073/pnas.171319698v1 [Abstract] [Full Text]  
• Lauer, G. M., Walker, B. D. (2001). Hepatitis C Virus Infection. NEJM 345: 41-52 [Full Text]  
• Polyak, S. J., Khabar, K. S. A., Paschal, D. M., Ezelle, H. J., Duverlie, G., Barber, G. N., Levy, D. E., Mukaida, N., Gretch, D. R. (2001). Hepatitis C Virus Nonstructural 5A Protein Induces Interleukin-8, Leading to Partial Inhibition of the Interferon-Induced Antiviral Response. J. Virol. 75: 6095-6106 [Abstract] [Full Text]  
• Polyak, S. J., Khabar, K. S. A., Rezeiq, M., Gretch, D. R. (2001). Elevated Levels of Interleukin-8 in Serum Are Associated with Hepatitis C Virus Infection and Resistance to Interferon Therapy. J. Virol. 75: 6209-6211 [Abstract] [Full Text]  
• Booth, J C L, O'Grady, J, Neuberger, J (2001). Clinical guidelines on the management of hepatitis C. Gut 49: I1-21 [Full Text]  
• Krekulova, L., Rehak, V., Wakil, A. E., Harris, E., Riley, L. W. (2001). Nested Restriction Site-Specific PCR To Detect and Type Hepatitis C Virus (HCV): a Rapid Method To Distinguish HCV Subtype 1b from Other Genotypes. J. Clin. Microbiol. 39: 1774-1780 [Abstract] [Full Text]  
• Cummings, K. J., Lee, S. M., West, E. S., Cid-Ruzafa, J., Fein, S. G., Aoki, Y., Sulkowski, M. S., Goodman, S. N. (2001). Interferon and Ribavirin vs Interferon Alone in the Re-treatment of Chronic Hepatitis C Previously Nonresponsive to Interferon: A Meta-analysis of Randomized Trials. JAMA 285: 193-199 [Abstract] [Full Text]  
• Koff, R. S. (2001). Nonresponse to Interferon in Chronic Hepatitis C: Re-treatment Redux. JAMA 285: 212-214 [Full Text]  
• Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M.-Y., Gane, E., O'Grady, J., Reichen, J., Diago, M., Lin, A., Hoffman, J., Brunda, M. J. (2000). Peginterferon Alfa-2a in Patients with Chronic Hepatitis C. NEJM 343: 1666-1672 [Abstract] [Full Text]  
• Zylberberg, H, Benhamou, Y, Lagneaux, J L, Landau, A, Chaix, M-L, Fontaine, H, Bochet, M, Poynard, T, Katlama, C, Pialoux, G, Brechot, C, Pol, S (2000). Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 47: 694-697 [Abstract] [Full Text]  
• Nousbaum, J.-B., Polyak, S. J., Ray, S. C., Sullivan, D. G., Larson, A. M., Carithers, R. L. Jr., Gretch, D. R. (2000). Prospective Characterization of Full-Length Hepatitis C Virus NS5A Quasispecies during Induction and Combination Antiviral Therapy. J. Virol. 74: 9028-9038 [Abstract] [Full Text]  
• Lai, V. C. H., Zhong, W., Skelton, A., Ingravallo, P., Vassilev, V., Donis, R. O., Hong, Z., Lau, J. Y. N. (2000). Generation and Characterization of a Hepatitis C Virus NS3 Protease-Dependent Bovine Viral Diarrhea Virus. J. Virol. 74: 6339-6347 [Abstract] [Full Text]  
• Martinot-Peignoux, M., Le Breton, V., Fritsch, S., Le guludec, G., Labouret, N., Keller, F., Marcellin, P. (2000). Assessment of Viral Loads in Patients with Chronic Hepatitis C with AMPLICOR HCV MONITOR Version 1.0, COBAS HCV MONITOR Version 2.0, and QUANTIPLEX HCV RNA Version 2.0 Assays. J. Clin. Microbiol. 38: 2722-2725 [Abstract] [Full Text]  
• Seiler, P., Senn, B. M., Klenerman, P., Kalinke, U., Hengartner, H., Zinkernagel, R. M. (2000). Additive Effect of Neutralizing Antibody and Antiviral Drug Treatment in Preventing Virus Escape and Persistence. J. Virol. 74: 5896-5901 [Abstract] [Full Text]  
• Fischer, L. R., Tope, D. H., Conboy, K. S., Hedblom, B. D., Ronberg, E., Shewmake, D. K., Butler, J. C. (2000). Screening for Hepatitis C Virus in a Health Maintenance Organization. Arch Intern Med 160: 1665-1673 [Abstract] [Full Text]  
• Aurisicchio, L., Delmastro, P., Salucci, V., Paz, O. G., Rovere, P., Ciliberto, G., La Monica, N., Palombo, F. (2000). Liver-Specific Alpha 2 Interferon Gene Expression Results in Protection from Induced Hepatitis. J. Virol. 74: 4816-4823 [Abstract] [Full Text]  
• Tam, R. C., Ramasamy, K., Bard, J., Pai, B., Lim, C., Averett, D. R. (2000). The Ribavirin Analog ICN 17261 Demonstrates Reduced Toxicity and Antiviral Effects with Retention of both Immunomodulatory Activity and Reduction of Hepatitis-Induced Serum Alanine Aminotransferase Levels. Antimicrob. Agents Chemother. 44: 1276-1283 [Abstract] [Full Text]  
• Zein, N. N. (2000). Clinical Significance of Hepatitis C Virus Genotypes. Clin. Microbiol. Rev. 13: 223-235 [Abstract] [Full Text]  
• SOMA, J., SAITO, T., TAGUMA, Y., CHIBA, S., SATO, H., SUGIMURA, K., OGAWA, S., ITO, S. (2000). High Prevalence and Adverse Effect of Hepatitis C Virus Infection in Type II Diabetic-Related Nephropathy. J. Am. Soc. Nephrol. 11: 690-699 [Abstract] [Full Text]  
• Gibb, D M, Neave, P E, Tookey, P A, Ramsay, M, Harris, H, Balogun, K, Goldberg, D, Mieli-Vergani, G, Kelly, D (2000). Active surveillance of hepatitis C infection in the UK and Ireland. Arch. Dis. Child. 82: 286-291 [Abstract] [Full Text]  
• (2000). The National Commission on Correctional Health Care and The Society of Correctional Physicians Joint Position Statement: The Management of Hepatitis C in Correctional Institutions. JOURNAL OF CORRECTIONAL HEALTH CARE 7: 149-155  
• Gutfreund, K. S., Bain, V. G. (2000). Chronic viral hepatitis C: management update. CMAJ 162: 827-833 [Abstract] [Full Text]  
• Dietrich, C. F., Stryjek-Kaminska, D., Teuber, G., Lee, J.-H., Caspary, W. F., Zeuzem, S. (2000). Perihepatic Lymph Nodes as a Marker of Antiviral Response in Patients with Chronic Hepatitis C Infection. Am. J. Roentgenol. 174: 699-704 [Abstract] [Full Text]  
• Liang, T. J., Rehermann, B., Seeff, L. B., Hoofnagle, J. H. (2000). Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C. ANN INTERN MED 132: 296-305 [Abstract] [Full Text]  
• Hofgärtner, W. T., Kant, J. A., Weck, K. E. (2000). Hepatitis C Virus Quantitation: Optimization of Strategies for Detecting Low-Level Viremia. J. Clin. Microbiol. 38: 888-891 [Abstract] [Full Text]